4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Frontage Holdings Corporation (1521) operates in the Biotechnology industry and is headquartered in Exton, United States with about 1,800 employees. Its market capitalization is roughly HK$2 billion. In the fiscal year ended 2025-12-31, 1521 reported $257M in revenue and $7M in net income.
Frontage Holdings Corporation provides drug discovery, drug development, pharmaceutical product development, and laboratory testing services to pharmaceutical, biotechnology, and agrochemical companies.
Interactive charts & full statements → Open the 1521 valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $257M | $255M | $260M | $250M |
| Gross Profit | $69M | $70M | $78M | $89M |
| Operating Income (EBIT) | $20M | $9M | $20M | $35M |
| Net Income | $7M | $1M | $11M | $26M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $541M | $554M | $572M | $551M | — |
| Total Liabilities | $193M | $219M | $227M | $215M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 1521 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms